louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05859399: The Effect of Laughter Yoga on Premenstrual Symptoms and Quality of Life in Midwifery Students
Official title: The Effect of Laughter Yoga on Premenstrual Symptoms and Quality of Life in Midwifery Students With Premenstrual Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Premenstrual Syndrome
Quality of Life
Keywords: Premenstrual Syndrome
Quality of life
Laughter yoga
Laughter therapy
Student
Lead sponsor: Mersin University
Sponsor class: OTHER
First posted: 2023-05-16
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, parallel, two arm, randomized controlled clinical trial
Primary purpose: SUPPORTIVE_CARE

Brief summary: The research was planned as a prospective, randomized controlled experimental study to determine the effect of laughter yoga applied to midwifery students on premenstrual symptoms (PMS) and quality of life.

Research Hypotheses H0: Online laughter yoga has no effect on premenstrual symptoms. H1: Online laughter yoga has an effect on premenstrual symptoms. H0: Online laughter yoga has no effect on quality of life. H1: Online laughter yoga has an impact on quality of life.

Detailed description: 59 midwifery students will participate in the research. In this study, the number of laughter yoga sessions was determined in line with the studies in the literature. Each laughter yoga session is planned to last approximately 40-45 minutes. Each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter.

Eligibility criteria: Inclusion Criteria:

* To agree to participate in the research,
* To be over 18 years old,
* Not having taken vocational courses
* Not having a chronic disease,
* Having a regular menstrual period,
* Having at least 110 points on the PMS scale
* Not receiving medical treatment for PMS.

Exclusion Criteria:

* Refusing to participate in the research,
* To have taken vocational courses,
* Having a chronic illness
* Getting a score lower than 110 on the PMS scale,
* Having any condition where laughter yoga should be avoided (having had abdominal surgery in the last three months, taking regular medications, epilepsy, uncontrollable hypertension, glaucoma, hernia, etc.)
* Receiving medical treatment for PMS.

Primary outcomes:
measure: Premenstrual Syndrome Scale (PMSS)
timeFrame: change from baseline, at the end of 12th week of intervention.
Secondary outcomes:
measure: World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF)
timeFrame: change from baseline, at the end of 12th week of intervention.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06560099: Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section
Official title: Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Post Partum Hemorrhage
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-08-19
Enrollment: 39
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Controlling hemorrhage during and after a cesarean section reduces significantly maternal mortality and morbidity and the present study is important for detection of the effectiveness of routinely increasing the oxytocin dose instead of using the standard dose only in preventing postpartum hemorrhage and additional use of uterotonics in the first 24 hours after cesarean section for high risk pregnancy.


Eligibility criteria: Inclusion Criteria:

* - Medical disorders ie: Hypertensive diseases with pregnancy - Diabetes Mellitus - Collagen diseases - Coagulopathies - Cardiac diseases - Anemia
* History of postpartum hemorrhage
* Placental disorders ie: placenta previa
* Infertility and ICSI
* High Parity
* History of Endometriosis
* Fetal disorders (IUGR, IUFD, Preterm, Congenital anomalies, oligohydramnios or polyhydramnios, macrosomia)
* Preterm labor on uterine relaxants
* Twins pregnancy
* Patients on antiplatelets and anticoagulants
* Uneventful antenatal care

Exclusion Criteria:

* - Oxytocin Allergy
* Normal uncomplicated pregnancy
* Emergency cesarean section
* Exhausted uterus due to trial of normal labor
* Couvelaire uterus

Primary outcomes:
measure: blood loss
timeFrame: at the end of the operation
Secondary outcomes:
measure: haemoglobin
timeFrame: immediate preoperative
measure: haemoglobin
timeFrame: 6 hours postoperative
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03886142: Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis
Official title: Efficacy of Genicular Nerve Radiofrequency Ablation Versus Intra-Articular Platelet Rich Plasma in Chronic Knee Osteoarthritis; a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteo Arthritis Knee
Pain, Chronic
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-03-22
Enrollment: 200
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: patients with chronic knee osteoarthritis non res ponders to conventional medical treatment
Primary purpose: TREATMENT

Brief summary: Osteoarthritis (OA) affects aged above 45 years. RF has been used for several painful conditions. There have been a few attempts to use RF current for the treatment of painful conditions of joints of the extremities. It was also used for the treatment of painful conditions of the hip joint.


Eligibility criteria: Inclusion Criteria:

* osteoarthritis knee

Exclusion Criteria:

* coaguloapthy
* patient refusal

Primary outcomes:
measure: pain visual analog scale
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Emad Zarief Kamel Said
Study officials:
References:
Clinical trial NCT00173342: Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization
Official title: Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bundle-Branch Block
Keywords: Right bundle branch block
Electrocardiography
Ion channel
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 50
Sex: ALL
Minimum age (years): 8
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: This study is to determine 1) the incidence of altered right bundle conduction, including CRBBB, IRBBB or rsR' pattern in the Taipei city based on the school survey databank from 1999 to 2002, 2) the associated cardiac lesions, 3) clinical presentations relevant to the altered right bundle conduction, 4) the association with QTc prolongation and dispersion and HRV from a 5-minutes recording. Finally, molecular characterization for those with CRBBB or Brugada pattern EKG, especially those with positive family history will be studied.

Detailed description: The EKG pattern and medical records from the school survey from 1999 to 2002 in Taipei city will be reviewed, and the basic data of those with CRBBB, IRBBB and rsR' pattern will be recorded. Interview will be made and the echocardiographic measurements will be performed to identify associated cardiac defects. EKG parameters and QT, QTc, QT dispersion, QTc dispersion and HRV parameters will be obtained from a semi-automated system. Time domain and frequency domain measures will be calculated and expressed as SDNN, triangular index, SDNN index, total power, low frequency power and high frequency power. Mutational analysis and DNA sequencing will be conducted in those with CRBBB or Brugada pattern EKG, especially those with positive family history.

Based on these data, the clinical significance of altered bundle branch conduction identified from a school survey may be defined. For those with isolated CRBBB or IRBBB, the adjunctive value of HRV and QT parameters will determined the high risk group, and 24 hour Holter recording and Treadmill exercise test will then perform in these patients to define association with ventricular arrhythmia.

Eligibility criteria: Inclusion Criteria:

* ECG showed right bundle branch block

Exclusion Criteria:

* can't tolerate Treadmill ECG study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Pediatrics, National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Pediatric Department, National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Mei-Hwan Wu, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05308342: Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Official title: Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Premature Ovarian Insufficiency
Lead sponsor: Nanjing University
Sponsor class: OTHER
First posted: 2022-04-04
Enrollment: 66
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was a single-center, randomized, controlled prospective study. Those who had premature ovarian failure and who had fertility requirements were enrolled in the study. To determine the efficacy and safety of umbilical cord mesenchymal stem cells in the treatment of patients with POI.

Detailed description: According to the enrollment and exclusion criteria, the patients were enrolled, and the subjects were randomly divided into two groups by computer randomization. Group A was hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells (test group). Group B was the hormone replacement group (control group).

Eligibility criteria: Inclusion Criteria:

1. Those who meet the POF diagnostic criteria and have no spontaneous follicular activity;
2. Married, 20 years old ≤ age \< 40 years old;
3. The average diameter of each ovary is \> 10 mm;
4. Have agreed to sign the informed consent form.

Exclusion Criteria:

1. Female and/or male chromosomal abnormalities;
2. Endometriosis, adenomyosis;
3. Postoperative ovarian borderline or malignant tumor;
4. Uterine dysplasia;
5. Associated with female autoimmune disease or other serious internal surgical diseases;
6. hormone replacement contraindications;
7. In the past 1 year, had received an experimental study of premature ovarian failure in the external hospital;
8. Male azoospermia or severe oligozoospermia.

Primary outcomes:
measure: Follicular development rate
timeFrame: 9-12 months
Secondary outcomes:
measure: Changes in blood flow index in the ovary
timeFrame: 9-12 months
measure: Clinical pregnancy rate
timeFrame: 9-12 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School
state: Jiangsu
Study officials:
affiliation: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
name: Guangshu Han, phD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06878742: Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants
Official title: Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Infant, Premature, Diseases
Circulatory and Respiratory Physiological Phenomena
Keywords: Hemodynamic insuffiency
Low superior vena cava flow
Lead sponsor: Instituto de Investigación Hospital Universitario La Paz
Sponsor class: OTHER
First posted: 2025-03-17
Enrollment: 30
Sex: ALL
Maximum age (years): 72
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: NeoCirc-002 is a single center, dose finding trial to define the minimum effective dose of dobutamine to treat early hemodynamic insufficiency in the preterm infant (less than 33 completed weeks' gestation), defined as presence of low SVC flow (\<51 ml/k/min) within the first 72 hours from birth.

The trial is a low-intervention clinical trial since dobutamine is the standard treatment for circulatory failure in preterm infants during transitional circulation, the dosages studied are within the standard therapeutic range, and the diagnostic supplementary procedures are in routine clinical practice.
Primary purpose: TREATMENT

Brief summary: Single centre, dose finding trial to establish the minimum effective dose of dobutamine required to treat hemodynamic insufficiency, defined as low superior vena cava (SVC) flow, in infants below 33 weeks' gestation during transitional circulation (first 72 hours from birth).


Eligibility criteria: Inclusion Criteria:

* Born with up to 32(+6) weeks gestation
* Presence of hemodynamic insufficiency, defined as SVC flow \<51 ml/kg/min.
* Provision of signed and dated informed consent form by father/mother or legally designated representative, which can be given antenatally.

Exclusion Criteria:

* Neonates considered non-viable, with a clinical decision not to provide life support
* Infants with severe congenital hydrops fetalis needing chest or peritoneal drainage before recruitment
* Infants already on dobutamine treatment
* Infants with congenital malformations likely to affect cardiovascular adaptation (including: congenital diaphragmatic hernia, gastroschisis or congenital heart defects)
* Infants with chromosomal anomalies
* Lack of parental signed informed consent

Primary outcomes:
measure: Minimum dobutamine dose to reach and maintain a SVC flow above 55 ml/kg/min
timeFrame: 1 and 3 hours
Secondary outcomes:
measure: Proportion of neonates achieving and maintaining a clinically acceptable haemodynamic status
timeFrame: 72 hours
measure: Absolute and relative frequencies of adverse events and severe adverse events
timeFrame: Through study completion, an average of 12 months
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Universitario Quironsalud
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
Study officials:
References:
Clinical trial NCT02843542: Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI)
Official title: Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Primary Hyperthyroidism
Keywords: Positron emission tomography-magnetic resonance imaging (PET-MR)
Hyperthyroidism
Positron emission tomography-computed tomography (PET-CT)
Lead sponsor: Assuta Medical Center
Sponsor class: OTHER
First posted: 2016-07-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: A comparative prospective study to evaluate different imaging modalities (pet-ct and pet-mr) prior to surgery in parathyroid tumor patients.

Detailed description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. in addition to the conservative 99mTc-MIBI (methoxyisobutylisonitrile) and US, patients will also undergo 18FCH (¹⁸F-choline) PET/MRI for detecting adenomas and their location. imaging experts will decode the imaging exams. sensitivity and specificity of the exams will be examined.

Eligibility criteria: Inclusion Criteria:

Patients who meet the criteria accepted in the World Health Organization (WHO) analysis:

* Symptomatic patients (constipation, depression, peptic ulcer, pathologic fractures, chronic fatigue, pain from a urinary tract stones etc..)

or at least one of the following criteria:

* Blood calcium levels above 1 more than normal
* Creatinine clearance decreased in 30% from age expected
* Urine Creatinine above 400 mg in 24 hours

Exclusion Criteria:

* Patients with hyperthyroidism secondary and tertiary (secondary to kidney disease)
* Patients who are not eligible to sign an informed consent
* Pregnant women
* Patients with sensitivity (allergy) technetium or 18FCH

Primary outcomes:
measure: Adenomas size and location
timeFrame: 24 months
Secondary outcomes:
measure: Parathyroid hormone levels
timeFrame: 24 months
measure: Chronic disease duration
timeFrame: 24 months
measure: Disease related medication consumption
timeFrame: 24 months
Other outcomes:
Locations:
city: Tel-Aviv
country: Israel
facility: Assuta Medical Center
Study officials:
affiliation: Assuta Medical Center
name: Avi hefetz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00762242: Metabolomic Profiling of Novel Mediators of Vascular Function
Official title: Metabolomic Profiling of Novel Mediators of Vascular Function
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Type 2 Diabetes Mellitus
Keywords: metabolomics
flow-mediated vasodilation
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2008-09-30
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The purpose of this study is to identify and characterize specific chemicals and metabolic pathways that change with forearm ischemia. These changes will be compared with forearm blood flow and flow-mediated vasodilation of the brachial artery.


Eligibility criteria: Inclusion Criteria:

* Adults age 18 or older
* Type 2 diabetes mellitus

Exclusion Criteria:

* Type 1 diabetes mellitus
* Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin \[pramlintide\]), or incretin mimetics (Byetta \[exenatide\])
* Pregnancy
* Uncontrolled hypertension, \> 180/100 mmHg

Primary outcomes:
measure: change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements
timeFrame: pre/post 5 minute ischemic stimulus
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Joshua A. Beckman, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02827942: Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication
Official title: Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gastritis Associated With Helicobacter Pylori
Keywords: pylori
Lead sponsor: Hamamatsu University
Sponsor class: OTHER
First posted: 2016-07-11
Enrollment: 112
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Comparison of the dual VPZ/AMPC therapy and triple VPZ/AMPC/CAM therapy
Primary purpose: TREATMENT

Brief summary: Patients infected with H. pylori were randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg or metronidazole 250 mg bid bid for 1 week. Success or failure of eradication was determined by the 13C-urea breath test performed at 1 month after the therapy.

Detailed description: Patients infected with H. pylori were enrolled and invited to the study.

Patients who have never undergone the H. pylori eradication therapy are randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week.

Patients who have ever failed in the eradication of H. pylori by the triple therapy containing clarithromycin are randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week.

Success or failure of eradication was determined by the 13C-urea breath test performed at 1 month after the therapy.

Eligibility criteria: Inclusion Criteria:

* Patients infected with H. pylori
* Patients who are not allergic to any of drugs used in this study
* Patients who agree to participate to the study patients who are treatment naive for eradication of H. pylori

Exclusion Criteria:

* Patients not infected with H. pylori
* Patients who are allergic to any of drugs used in this study
* Patients who do not agree to participate to the study
* Severe general condition, such as renal insufficiency or liver dysfunction
* History of gastrectomy
* Inability to undergo eradication therapy
* Patients who have ever undergone the eradication therapy for H. pylori infection

Primary outcomes:
measure: The success or failure of eradication
timeFrame: 4 to 8 weeks after the end of the eradication therapy
Secondary outcomes:
measure: Adverse events
timeFrame: 1 week
Other outcomes:
Locations:
city: Hamamatsu
country: Japan
facility: Hamamatsu University School of Medicine
state: Shizuoka
Study officials:
affiliation: Hamamatsu University
name: Takahisa Furuta, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02093442: Endometrial Scratching for Cryopreserved Embryo Transfer
Official title: Endometrial Scratching for Cryopreserved Embryo Transfer: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Subfertility
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2014-03-21
Enrollment: 62
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Endometrial injury performed in a cycle preceding the one for embryo transfer is associated with an increased implantation and pregnancy rate when carried out during the month preceding that of ovulation induction and fresh embryo transfer. However, there is no evidence about the effect of this intervention on the transfer of cryopreserved embryos.


Eligibility criteria: Inclusion Criteria:

* Age \> 18
* At least one cryopreserved embryo

Exclusion Criteria:

* None

Primary outcomes:
measure: Live birth
timeFrame: 10 months
Secondary outcomes:
measure: Clinical pregnancy
timeFrame: 3 months
measure: Miscarriage
timeFrame: 5 months
Other outcomes:
measure: Multiple pregnancy
timeFrame: 3 months
Locations:
city: Ribeirao Preto
country: Brazil
facility: Setor de Reprodução Humana - FMRP-USP
state: SP
Study officials:
affiliation: University of Sao Paulo
name: Wellington P Martins, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: